Drug Profile
Apraglutide - Ironwood Pharmaceuticals
Alternative Names: FE 203799; GLP2 analouge; Glucagon-like peptide-2 receptor agonist - Ferring Pharmaceuticals/Ironwood PharmaceuticalsLatest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Ferring Pharmaceuticals
- Developer Ironwood Pharmaceuticals; Therachon
- Class Glucagon-like peptides
- Mechanism of Action Glucagon-like peptide 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Short bowel syndrome
- Phase II Graft-versus-host disease
- Phase I Unspecified
- No development reported Gastrointestinal disorders
Most Recent Events
- 28 Mar 2024 Efficacy and adverse event data from the phase II STARGAZE trial in Graft-versus-host disease released by Ironwood Pharmaceuticals
- 14 Mar 2024 Ironwood plans to submit a NDA and other regulatory filings for apraglutide for use in adult patients with Short bowel syndrome who are dependent on parenteral support
- 29 Feb 2024 Topline efficacy and adverse events data from a phase III STARS trial in Short bowel syndrome released by Ironwood Pharmaceuticals